Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I just got off the phone with an absolutely lovely person from Patient Assistance, I only wish her message to me was as pleasant as her demeanor. In Northern, NJ, she provided the following list of Medicare Advantage/Supplemental Drug Plan Providers:
Provider Coverage Tier
Aetna T2
AmeriVantage T4
CarePoint Health T4
CVS T3 ???
Coventry T2
Express Scripts T2
HealthFirst Medicare Advant T3
Kaiser Medicare T4
RiteAid Envision T3
ScriptCare T4
UHC T4
HD, the problem is the phrasing from Amarin, they said "to 2015" not "through 2015". "To 2015" does not include 2015.
Exactly right Dew, but in my region, many of those negotiations have excluded Vascepa. Some prominent names include most of the plans from UHC/AARP, Horizon BC/BS and Humana! I'm still searching for a Medicare Advantage or Part D Supplemental plan that will cover Vascepa. The more I look, the more restrictions I see!
Zuman and Dew, the prescription growth will screech to a halt very shortly if Amarin doesn't find a way to keep Vascepa on the "Covered Drugs" lists of major Pharmaceutical Managers. My research is showing me that more and more Formularies have had Vascepa removed and the suggested replacement is Lovaza. Amarin has not addressed this except to say they have Tier Status through November 2014. What about 2015 guys? This is becoming more critical every day!
Not sure if you noticed ZU, but Dr. Barry Sears appears on Page 14 (Topic 26) describing the use of the AA/EPA ratio as a surrogate marker for adequate levels of O-3 Fatty Acids to generate sufficient amounts of inflammation pro-resolution mediators. He's involved in an open pilot study using high dose DHA and EPA as a treatment for Dry Age-related Macular Degeneration. Go get 'em Doc!
Another surprising thought struck me while perusing the list of research topics....the vast majority referred to effects of Resolvins metabolized from DHA (RvD) instead of EPA (RvE). I would have expected much more from EPA.
All I can add to this is, "You asked for it, Posi" and "Well said, Ciroc!" And a good day to all! (now that was funny!)
It is just so difficult to listen to this FDA bullshit without bile backing up in my throat. They couch themselves in virtue but they know they are not virtuous! It's disgusting.
Once again Zu, if she really wants to do her readers some good, she should be telling them about Vascepa and skip the Ezetimibe spin doctoring!
Zu, Barbara Streisand has taken up the call and has initiated a vendetta on the silent, deadly killer of women, Heart Disease. She had a media blitz over the last few weeks where she showed up on broadcasts all over the place touting the differences in symptoms between women and men having an acute heart-related episode. She had three interviews with Katie Couric who did the on-air colonoscopy after her husband died from Colon Cancer. If anyone has the BALLS to get the word out and tell it like it is on RLP-C and RLP-TG and the harm it causes women, AND the benefit that Vascepa in combo with a Statin can offer, IT IS THESE TWO LADIES! Can anyone think of a way to get this information into their hands? I've racked my feeble brain but I'm just not connected, maybe the EPADI? Neither Margaret nor Janet at FDA would stand a chance against them!
Hey Merck.....you want a Combo? Screw Ezetimibe....get some EPA, now you got a Combo!
Great study RD, unfortunately it was Japanese and we know what that means........
When the history of Amarin and Vascepa is finally written, it will be the Greatest Story Ever Told or it will be the saddest story ever told......there will be no middle ground.
There are numerous formularies that are modifying coverage of Vascepa. I just received a notice from my CVS plan which covers 35,000 lives in my company that Vascepa will not be covered in 2015. It is being replaced by Lovaza....interestingly not by Lovaza generic.
If Amarin doesn't do something to shore up relationships with these Pharmacy Providers, we're going to need a miracle to get to the end of Reduce-It. Lack of coverage as a result of FDA failure to upgrade the label will be our death blow!
I'll take a wager, premium beer at the Vegas Tournament?!?!
Yeah, it is. I think I recall you saying you rolled into TD and TE warrants, they'll make it back to your buy-in price quickly. I'm also mainly in TD and TE warrants and I hold 15k shares. Big paper hit today but no long term fear!
Not until the PPS breaks $4.00, maybe May/June.....
CPTJSD, you should try to be calm......going forward, you will have many opportunities to trade out of your warrant positions. You will recoup your paper loss from today and make substantial profits way before anything expires!
Well, maybe you're right.
Hi elcaribes, there are 100 Million shares of Titan in the float. Today we've traded just over 200 Thousand of them. You needn't worry about being trampled by the crowd because no one is rushing toward the doors!
True Kiwi, but the benefit of the gene mutation is that it provides protection over a long duration, i.e from birth, as opposed to Ezetimibe which would be introduced at some later time in one's life.
Excellent opportunity to buy at bargain prices! Maybe there'll be a Black Friday Sale at $1.60!
Let's see, I can stay here and read the posts from elcaribes or I can head out and get that double root canal I've been avoiding. Mmmmm....see you guys later!
Actually many of the investors are growing terribly weary of the INCESSANT NOISE, COMPRENDEZ!
Interesting AP, along with the sidestepping, there might have been some back pedaling on the part of these panelists. Sounds like maybe Ezetimibe may not have added much to Simvastatin. Considering the most recent lipid science, much of which has been highlighted on this board by the Zuman, that doesn't really surprise me. Of course and as usual, discussing bad news for a totally separate organization seems to have triggered a PPS drop for Amarin....LOL!
Yes, it's just too bad that the FDA and the US Physician base don't consider the Japanese subjects to be full-fledged human beings!
.....and take your thumb off the SHIFT Key!
(deleted)
That's a sentiment that I'm also proud to echo.....thank you and bless you all for your service to this country!
How and why did 403,000 shares trade at 4:06PM?
Ziploc, if as you suggest, "the revenue continues to go downhill", then I would enthusiastically agree that Amarin roll the dice and unblind the trial. However, I believe we have a long way to go before that becomes necessary. They have significant cash available, the drug is selling and financials may still improve. Events aren't happening at the pace we want but if you've stuck with it this far, it's a little early to throw in the towel. That said, I'd really appreciate something responsive from this group of A..Holes running this company!
deleted
You don't need to be listed on a US Exchange to proceed with a Buyout!
Don't want to keep bothering BioBill so does anybody on the Board have a list of FDA email addresses?
BB, sorry but will you publish FDA email addresses again?
52gallery, many would agree with you. Wonderful idea and others have been trying......see the EpaDrugInitiative.com website if you haven't already done so. Trouble is that it's much harder than anyone would think to get the message into the hands of those with a broad audience. UNLESS, you have really deep pockets!
BB, which CP is that?
The problem with these Japanese studies is that US agencies (FDA, AHA, ADA, etc) seem to believe that Japanese physiology and American physiology are somehow inherently different. They are reluctant to accept trial results unless done on an American population.
Out of curiousity, if a BP were to run a large trial on the basis of this study using some other EPA source, would Vascepa patents still be relevant? That is, if this specific EPA therapeutic effect was demonstrated, would Vascepa still benefit?
Quote:
------------------------------------------------------------------------
"Frankly , I don't see how your efforts help Amarin"
------------------------------------------------------------------------
You know, Kiwi, you might want to spend some time contemplating the gist of your quote above. If you're honest about it, I think you might have to concede that for the last 3 or 4 months, it pretty clearly applies to your own efforts as well. IMHO, I think you've made the point that you're a smart guy. Don't you think it's about time you ended the pissing contest(s)?
BB: Used "karenkennard@fda.hhs.gov" to send her Email but got rejected with invalid address. Do I have her Email right?
DOCTOR Gupta is a mainstream MD, there is no way he'd take on the AHA or the FDA. He won't go against conventional thinking! Too bad actually.
Or maybe this will make a better headline for "60 Minutes" ---
"What Really Killed Tim Russert? Was It His Heart or Was It Big Pharma and the FDA?"